NCT02267512 is a Phase 4 clinical trial of ATG-F in De Novo Kidney Transplant Patients, sponsored by Astellas Pharma Inc.

Who is sponsoring NCT02267512?

NCT02267512 is sponsored by Astellas Pharma Inc.

What drugs are being tested in NCT02267512?

Interventions in NCT02267512: ATG-F.

What condition does NCT02267512 study?

NCT02267512 studies De Novo Kidney Transplant Patients.

Is NCT02267512 still recruiting?

NCT02267512 is currently completed. Last updated 1 November 2024.

Last reviewed 2024-11-01 · How we verify

NCT02267512

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients

Completed Phase 4 Last updated 1 November 2024

What this trial tests

Phase 4 trial testing ATG-F in De Novo Kidney Transplant Patients in 280 participants. Completed in 31 December 2015.

Timeline

31 July 2012

Primary endpoint
31 December 2015

31 December 2015

Quick facts

Lead sponsor	Astellas Pharma Inc
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	280
Start date	31 July 2012
Primary completion	31 December 2015
Estimated completion	31 December 2015
Sites	14 locations across China

Drugs / interventions tested

ATG-F — full drug profile →

Conditions studied

De Novo Kidney Transplant Patients — all drugs for De Novo Kidney Transplant Patients →

Sponsor

Astellas Pharma Inc — full company profile →

Who can join

Adults 18 to 65, any sex, with De Novo Kidney Transplant Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the efficacy and safety of ATG-F induction regimen using a single dose of ATG-F compared with a five-day dose regimen of ATG-F in anew kidney transplant recipients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ATG-F

Trials testing the same drug.

NCT02523768 — Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basilixim · Phase 4 · terminated

Other Astellas Pharma Inc trials

Trials by the same sponsor.

NCT07318714 — A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke · Phase 1, PHASE2 · recruiting
NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06364696 — A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors · Phase 1 · active not recruiting
NCT06206421 — A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02267512 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Inc
Last refreshed: 1 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02267512.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing